FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings

Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinom...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of nuclear medicine and molecular imaging Vol. 30; no. 2; pp. 288 - 295
Main Authors Stahl, Alexander, Ott, Katja, Weber, Wolfgang, Becker, Karen, Link, Thomas, Siewert, Jörg-Rüdiger, Schwaiger, Markus, Fink, Ulrich
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.02.2003
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.
AbstractList Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7±3.4 vs 4.8±2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2±3.2 vs 3.9±2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4±2.3 vs 5.2±3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.
Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.
Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.
Author Stahl, Alexander
Siewert, Jörg-Rüdiger
Fink, Ulrich
Link, Thomas
Schwaiger, Markus
Ott, Katja
Weber, Wolfgang
Becker, Karen
Author_xml – sequence: 1
  givenname: Alexander
  surname: Stahl
  fullname: Stahl, Alexander
– sequence: 2
  givenname: Katja
  surname: Ott
  fullname: Ott, Katja
– sequence: 3
  givenname: Wolfgang
  surname: Weber
  fullname: Weber, Wolfgang
– sequence: 4
  givenname: Karen
  surname: Becker
  fullname: Becker, Karen
– sequence: 5
  givenname: Thomas
  surname: Link
  fullname: Link, Thomas
– sequence: 6
  givenname: Jörg-Rüdiger
  surname: Siewert
  fullname: Siewert, Jörg-Rüdiger
– sequence: 7
  givenname: Markus
  surname: Schwaiger
  fullname: Schwaiger, Markus
– sequence: 8
  givenname: Ulrich
  surname: Fink
  fullname: Fink, Ulrich
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14608226$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12552348$$D View this record in MEDLINE/PubMed
BookMark eNp9kcluFDEQhi0URBZ4AC7IQoJbEy_dXrihbESKFA7hbHm8zDjy2IPtAeXt42YGIuUQWa7y4asq1_8fg4OUkwPgPUZfMEL8tCJEJjn0OGBE5DC9AkeYYTlwJOTB_zdHh-C41nuEsCBCvgGHmEwToaM4AuXy_Ar-uLiDYa2XIS1h9jBmo2N8gNr-1sk4C5e6thIMNLqYkPJa16_Q5FJc1C3kBP-EtoIu2VxN3nROJwtXoba80W2VY16G3hD6kGyfUN-C117H6t7t8wn4eXlxd_Z9uLm9uj77djMYOo1tkNxwbeno0CQIs9w7zx12FGlBrGGWLeYrPaHCaskI9cITTwlfMLegZKIn4POu76bkX1tXm1qHalyMOrm8rYoTKQSVrIMfn4H3eVtS_5sieGT9CNyhD3tou1g7qzalK1Ye1D8pO_BpD-ja1_WlaxfqEzcyJAiZp-EdZ0qutTj_hCA126p2tqoe1Wyrmlfhz2pMaH-1b0WH-ELlIxBVpq8
CitedBy_id crossref_primary_10_1097_MCP_0000000000000297
crossref_primary_10_1016_j_ejrad_2017_06_022
crossref_primary_10_1016_j_semradonc_2012_09_001
crossref_primary_10_1007_BF02984984
crossref_primary_10_1158_1078_0432_CCR_04_0599
crossref_primary_10_2342_ymj_57_171
crossref_primary_10_1007_s00423_011_0805_8
crossref_primary_10_1089_cbr_2017_2186
crossref_primary_10_1097_MNM_0000000000001481
crossref_primary_10_1002_jso_21356
crossref_primary_10_1016_S0123_9015_11_70078_6
crossref_primary_10_1016_j_rcl_2004_08_003
crossref_primary_10_1007_s10147_013_0598_6
crossref_primary_10_1055_s_0041_1735217
crossref_primary_10_1111_j_1759_7714_2011_00060_x
crossref_primary_10_1097_MD_0000000000016690
crossref_primary_10_4251_wjgo_v14_i8_1406
crossref_primary_10_1021_acsmedchemlett_6b00498
crossref_primary_10_1002_jso_24190
crossref_primary_10_7704_kjhugr_2013_13_3_158
crossref_primary_10_1016_j_mpmed_2015_01_007
crossref_primary_10_1007_BF03034001
crossref_primary_10_1097_MNM_0000000000001489
crossref_primary_10_1007_s00259_019_04429_x
crossref_primary_10_1007_s00432_010_0852_5
crossref_primary_10_1186_s12957_015_0743_y
crossref_primary_10_1007_s00259_008_0970_3
crossref_primary_10_5230_jgc_2014_14_1_1
crossref_primary_10_1007_s10120_006_0374_7
crossref_primary_10_1053_j_semnuclmed_2004_03_005
crossref_primary_10_1097_RLU_0000000000005748
crossref_primary_10_1245_s10434_024_15103_4
crossref_primary_10_12812_ksms_2015_17_1_111
crossref_primary_10_1007_s00259_020_04977_7
crossref_primary_10_47102_annals_acadmedsg_V33N2p186
crossref_primary_10_1007_s00261_020_02503_9
crossref_primary_10_1177_0300060519892417
crossref_primary_10_5230_jgc_2012_12_3_179
crossref_primary_10_4166_kjg_2014_63_6_348
crossref_primary_10_1259_bjr_29946900
crossref_primary_10_4166_kjg_2012_59_5_347
crossref_primary_10_4166_kjg_2013_61_6_303
crossref_primary_10_3892_mco_2018_1767
crossref_primary_10_7704_kjhugr_2013_13_3_133
crossref_primary_10_1097_RLU_0000000000004764
crossref_primary_10_1097_01_mnm_0000134329_30912_49
crossref_primary_10_4166_kjg_2014_63_2_66
crossref_primary_10_1016_j_ejso_2008_11_010
crossref_primary_10_1007_s10120_008_0492_5
crossref_primary_10_2967_jnmt_116_181479
crossref_primary_10_1002_cncr_27550
crossref_primary_10_1007_s00261_008_9420_8
crossref_primary_10_1007_s10120_007_0448_1
crossref_primary_10_1155_2013_696423
crossref_primary_10_1016_j_cpet_2008_09_002
crossref_primary_10_12677_ACM_2023_13102132
crossref_primary_10_1097_RLU_0b013e31823ea44d
crossref_primary_10_1186_s12885_017_3271_z
crossref_primary_10_1007_s00259_007_0477_3
crossref_primary_10_6004_jnccn_2022_0008
crossref_primary_10_1007_s00104_011_2127_3
crossref_primary_10_1007_s00261_016_0647_5
crossref_primary_10_1007_s10120_011_0069_6
crossref_primary_10_1186_s43055_019_0067_y
crossref_primary_10_1200_JCO_2014_59_9787
crossref_primary_10_5230_jgc_2018_18_e23
crossref_primary_10_1067_j_cpsurg_2006_06_003
crossref_primary_10_1200_JCO_2006_06_7801
crossref_primary_10_1016_j_bpg_2005_08_001
crossref_primary_10_1111_j_1442_2050_2006_00617_x
crossref_primary_10_1007_s40336_024_00633_4
crossref_primary_10_1183_16000617_0065_2018
crossref_primary_10_1007_s00330_019_06370_x
crossref_primary_10_1097_RLU_0b013e3181b81d80
crossref_primary_10_1007_s13139_019_00622_w
crossref_primary_10_1007_s00104_006_1270_8
crossref_primary_10_1007_s00104_009_1731_y
crossref_primary_10_1016_j_gtc_2018_04_011
crossref_primary_10_1007_s00268_003_7191_5
crossref_primary_10_1155_2018_1794524
crossref_primary_10_1016_j_rcl_2021_06_001
crossref_primary_10_1016_S0399_8320_06_73306_1
crossref_primary_10_4166_kjg_2014_64_6_340
crossref_primary_10_1097_MD_0000000000000864
crossref_primary_10_1053_j_semnuclmed_2005_12_002
crossref_primary_10_1007_s00261_005_0031_3
crossref_primary_10_3109_07357907_2014_911877
crossref_primary_10_1016_j_lpm_2007_03_048
crossref_primary_10_3390_cancers3022141
crossref_primary_10_1097_MNM_0b013e3283299a2f
crossref_primary_10_1159_000350878
crossref_primary_10_1016_j_radonc_2010_07_019
crossref_primary_10_2967_jnumed_120_258467
crossref_primary_10_3413_Nukmed_0504_12_05
crossref_primary_10_1007_s12149_013_0791_8
crossref_primary_10_1097_01_cco_0000128276_13585_fa
crossref_primary_10_1245_s10434_011_1743_y
crossref_primary_10_1007_s13139_015_0327_3
crossref_primary_10_4274_nts_galenos_2024_0011
crossref_primary_10_1111_ajco_12833
crossref_primary_10_1007_s10120_018_0847_5
crossref_primary_10_1016_j_rcl_2020_11_002
crossref_primary_10_1016_j_ejro_2020_01_001
crossref_primary_10_1007_s10120_021_01223_3
crossref_primary_10_3892_mco_2019_1815
crossref_primary_10_4103_ijnm_ijnm_69_24
crossref_primary_10_1007_s11604_014_0294_0
crossref_primary_10_1186_s43055_021_00656_1
crossref_primary_10_2967_jnumed_107_050187
crossref_primary_10_1007_s00423_010_0738_7
crossref_primary_10_1007_s10120_012_0165_2
crossref_primary_10_1038_sj_bjc_6604062
crossref_primary_10_1158_1078_0432_CCR_07_0934
crossref_primary_10_1157_13079285
crossref_primary_10_1001_jamasurg_2021_5340
crossref_primary_10_1002_cncr_21074
crossref_primary_10_1016_j_clinimag_2011_12_014
crossref_primary_10_1016_j_suc_2020_02_004
crossref_primary_10_1245_s10434_014_3848_6
crossref_primary_10_1097_MNM_0000000000001761
crossref_primary_10_3348_kjr_2006_7_4_249
crossref_primary_10_1159_000381287
crossref_primary_10_1016_j_ejrad_2010_02_005
crossref_primary_10_1097_RLU_0000000000000667
crossref_primary_10_1016_j_cpet_2015_03_008
crossref_primary_10_1200_JCO_2003_06_574
crossref_primary_10_1007_s00259_010_1611_1
crossref_primary_10_1016_S1879_8527_12_55045_8
crossref_primary_10_5230_jgc_2023_23_e11
crossref_primary_10_1002_jcla_22364
crossref_primary_10_1016_j_critrevonc_2005_09_004
crossref_primary_10_1245_s10434_009_0387_7
crossref_primary_10_1016_j_cpet_2025_01_004
crossref_primary_10_1007_s13139_010_0058_4
crossref_primary_10_3748_wjg_v21_i37_10502
crossref_primary_10_1007_s00761_005_0881_x
crossref_primary_10_1007_s12149_016_1059_x
crossref_primary_10_1007_s00761_008_1333_1
crossref_primary_10_1016_j_ejrad_2013_01_021
crossref_primary_10_1007_s00261_016_0788_6
crossref_primary_10_1016_j_ejro_2020_100268
crossref_primary_10_5230_jgc_2014_14_2_87
crossref_primary_10_1200_JCO_2011_39_7422
crossref_primary_10_2169_internalmedicine_0013_17
crossref_primary_10_1159_000436972
crossref_primary_10_1007_s11377_010_0432_x
crossref_primary_10_1371_journal_pone_0166836
crossref_primary_10_1093_annonc_mdq289
crossref_primary_10_1007_s00595_020_02018_2
crossref_primary_10_1007_s12149_007_0061_8
crossref_primary_10_1007_s12149_009_0291_z
crossref_primary_10_1016_j_ejrad_2013_01_014
crossref_primary_10_2217_iim_12_5
crossref_primary_10_4103_ijnm_ijnm_208_21
crossref_primary_10_1007_s00259_022_05799_5
crossref_primary_10_1016_j_dld_2015_02_005
crossref_primary_10_1007_s00104_007_1381_x
crossref_primary_10_1016_j_soc_2011_09_005
crossref_primary_10_1080_00365520903121701
crossref_primary_10_1097_01_rlu_0000255241_97811_4d
crossref_primary_10_24938_kutfd_1014164
crossref_primary_10_1007_s00259_015_3249_5
crossref_primary_10_1148_rg_245035725
crossref_primary_10_18632_oncotarget_11574
crossref_primary_10_2967_jnumed_115_160580
crossref_primary_10_9738_INTSURG_D_16_00006_1
crossref_primary_10_1016_j_rcl_2013_05_003
crossref_primary_10_1186_s40001_023_00997_9
crossref_primary_10_1007_s10120_024_01484_8
crossref_primary_10_1007_s00330_009_1405_7
crossref_primary_10_1371_journal_pone_0050914
crossref_primary_10_3390_cancers14112668
crossref_primary_10_1007_s00259_012_2164_2
crossref_primary_10_3390_curroncol29090513
crossref_primary_10_3390_ijms21114012
crossref_primary_10_2967_jnumed_114_150946
crossref_primary_10_1155_2019_9564627
crossref_primary_10_2967_jnumed_115_163295
crossref_primary_10_1007_s00261_019_02065_5
crossref_primary_10_1186_1471_2407_9_73
crossref_primary_10_3389_fonc_2024_1427649
crossref_primary_10_1097_MNM_0b013e32833823ac
crossref_primary_10_1002_jso_23180
crossref_primary_10_1007_s00259_022_06021_2
crossref_primary_10_1016_j_suc_2012_07_011
crossref_primary_10_1016_j_ijscr_2017_05_026
crossref_primary_10_1097_01_mnm_0000135042_54461_f6
crossref_primary_10_3390_cancers13030420
crossref_primary_10_1007_s00259_022_06095_y
crossref_primary_10_1007_s13139_013_0243_3
crossref_primary_10_1053_j_semnuclmed_2015_03_002
crossref_primary_10_1177_15330338241277389
crossref_primary_10_1007_s00259_012_2116_x
crossref_primary_10_1007_s10120_017_0739_0
crossref_primary_10_2967_jnumed_112_110239
crossref_primary_10_1177_17588359211065153
crossref_primary_10_1097_01_rlu_0000191575_85516_ef
crossref_primary_10_2967_jnumed_116_182675
crossref_primary_10_1007_s00259_021_05441_w
crossref_primary_10_5230_jgc_2025_25_e11
crossref_primary_10_1007_BF02984649
crossref_primary_10_3389_fsurg_2018_00041
crossref_primary_10_1007_s11605_014_2701_3
crossref_primary_10_3748_wjg_v21_i19_5901
crossref_primary_10_1007_s10120_011_0017_5
crossref_primary_10_1148_rg_261055078
crossref_primary_10_1016_j_suronc_2018_11_002
crossref_primary_10_1007_s00330_022_08743_1
crossref_primary_10_1097_RLU_0000000000002028
crossref_primary_10_2169_internalmedicine_48_1858
crossref_primary_10_3390_cancers6041821
crossref_primary_10_1007_BF02984657
crossref_primary_10_1007_s00259_005_1887_8
crossref_primary_10_1007_s13139_012_0149_5
crossref_primary_10_1148_radiol_2020203275
crossref_primary_10_1002_jso_21224
crossref_primary_10_1016_j_giec_2008_05_006
ContentType Journal Article
Copyright 2003 INIST-CNRS
Springer-Verlag 2003
Copyright_xml – notice: 2003 INIST-CNRS
– notice: Springer-Verlag 2003
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TK
7X7
7XB
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
P5Z
P62
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s00259-002-1029-5
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
ProQuest Health & Medical Collection
Proquest Medical Database
Biological Science Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Collection
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Advanced Technologies & Aerospace Database
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1619-7089
EndPage 295
ExternalDocumentID 819051731
12552348
14608226
10_1007_s00259_002_1029_5
Genre Validation Studies
Evaluation Studies
Journal Article
Case Reports
Report
Case Study
GroupedDBID ---
-Y2
-~C
.86
.GJ
04C
06C
06D
0R~
0VY
1N0
29G
29~
2JN
2JY
2LR
2P1
2VQ
2~H
36B
4.4
406
40D
53G
5GY
5QI
5RE
5VS
6NX
78A
7RV
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8UJ
95-
95.
95~
AACDK
AAHNG
AAIAL
AAJBT
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYQN
AAYTO
AAYXX
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDBF
ABECU
ABFSG
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABLJU
ABMNI
ABMQK
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACIWK
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSTC
ACUDM
ACUHS
ACZOJ
ADBBV
ADHIR
ADHKG
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFEXP
AFFNX
AFHIU
AFJLC
AFKRA
AFLOW
AFOHR
AFQWF
AFRAH
AFWTZ
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGVAE
AGWIL
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AOCGG
ARAPS
ATHPR
AXYYD
AYFIA
AZFZN
B-.
B0M
BA0
BBNVY
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
CITATION
COF
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBLON
EBO
EBS
EBX
EHN
EIHBH
EIOEI
EJD
EMB
EMK
EMOBN
EN4
EPL
EPT
ESX
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FSGXE
FYUFA
G-Y
G-Z
GGCAI
GNWQR
GQ7
GRRUI
H13
HCIFZ
HF~
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IZIGR
IZQ
I~X
I~Z
J-C
JBSCW
JCJTX
JZLTJ
KDC
KPH
LAS
LK8
LLZTM
M1P
M4Y
M7P
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O9G
OAM
OVD
P19
P62
P9S
PF0
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
Q~Q
R89
R9I
RNI
RNS
ROL
RPX
RSV
RZK
S1Z
S26
S27
S28
S37
SAP
SCLPG
SDH
SISQX
SJYHP
SMD
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
T13
T16
TEORI
TH9
TSG
TSK
TT1
TUS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VFIZW
W23
W48
WK8
WOW
YLTOR
Z8Z
ZMTXR
~8M
ABRTQ
IQODW
PJZUB
PPXIY
PQGLB
-5E
-5G
-BR
.VR
199
203
2KM
30V
3V.
67Z
96X
AAAVM
ABNWP
ABPLI
ADINQ
ALWAN
ARMRJ
CGR
CUY
CVF
DL5
ECM
EIF
ESBYG
FRRFC
FWDCC
GGRSB
GQ6
GQ8
GXS
HG5
I09
ITM
IXC
J0Z
NPM
O93
O9I
O9J
QOR
QOS
RRX
S3B
SNE
SZN
U2A
U9L
VC2
Z45
Z7R
Z7U
Z7W
Z7X
Z7Y
Z7Z
Z81
Z82
Z83
Z87
Z88
Z8M
Z8O
Z8Q
Z8R
Z8S
Z8T
Z8U
Z8V
Z8W
Z91
7TK
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
PUEGO
7X8
ID FETCH-LOGICAL-c354t-97c7ad34e05826d7fef7e1e30a82dc6d6b6d6b9f238da9623f8f2f327b6eb3253
IEDL.DBID 7X7
ISSN 1619-7070
IngestDate Fri Jul 11 12:03:24 EDT 2025
Sat Aug 23 13:39:35 EDT 2025
Wed Feb 19 01:36:25 EST 2025
Mon Jul 21 09:17:31 EDT 2025
Tue Jul 01 02:19:39 EDT 2025
Thu Apr 24 23:05:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Radionuclide study
Human
Stomach
Focal lesion
Carcinoma
Malignant tumor
Pathology
Cohort study
Digestive diseases
Advanced stage
Diagnosis
Endoscopy
Pharmacokinetics
Radiopharmaceuticals
Comparative study
Gastric disease
Positron
Emission tomography
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c354t-97c7ad34e05826d7fef7e1e30a82dc6d6b6d6b9f238da9623f8f2f327b6eb3253
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
content type line 23
ObjectType-Feature-5
ObjectType-Undefined-3
ObjectType-Article-4
PMID 12552348
PQID 214646481
PQPubID 42802
PageCount 8
ParticipantIDs proquest_miscellaneous_72988396
proquest_journals_214646481
pubmed_primary_12552348
pascalfrancis_primary_14608226
crossref_primary_10_1007_s00259_002_1029_5
crossref_citationtrail_10_1007_s00259_002_1029_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-02-01
PublicationDateYYYYMMDD 2003-02-01
PublicationDate_xml – month: 02
  year: 2003
  text: 2003-02-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle European journal of nuclear medicine and molecular imaging
PublicationTitleAlternate Eur J Nucl Med Mol Imaging
PublicationYear 2003
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
SSID ssj0018289
Score 2.2203498
Snippet Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 288
SubjectTerms Biological and medical sciences
Digestion. Liver. Biliary tract. Spleen. Pancreas
Fluorodeoxyglucose F18
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Gastroscopy - methods
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Observer Variation
Prognosis
Radionuclide Imaging
Radionuclide investigations
Radiopharmaceuticals
Reference Values
Reproducibility of Results
Retrospective Studies
Sensitivity and Specificity
Single-Blind Method
Statistics as Topic
Stomach Neoplasms - diagnosis
Stomach Neoplasms - diagnostic imaging
Stomach Neoplasms - mortality
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Analysis
Survival Rate
Tumors
Title FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings
URI https://www.ncbi.nlm.nih.gov/pubmed/12552348
https://www.proquest.com/docview/214646481
https://www.proquest.com/docview/72988396
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB61IKFKqCotjy1l60NPlSKysRM7XBALG1AlEKpA2luU-LFCgmQhy6H_vjPOA3EARXEOsX3w2OP5POP5AH4JlQqXIlJ1JWITVHgyKKWyAY_tRDghrA7pcvLlVXJxK_7M43kXm9N0YZW9TvSK2tSazsgPiYAaHzU5Xj4GRBpFztWOQeMjrFPmMorokvMBb00ITBDeQowQSJzavVMz9DlE0e4PPLMHBYDEr7alzWXR4Ai5ltribdvT70HZF_jcGY_spJX2Fnyw1VfYuOzc49_gKTs7Z9ezG3b34MmHWO2Y36zu_7He2c8WBVF1aKaJRaii8KAjpomjo42KY3Qyy2xlarqwgvWKyjCflZjIi3tVybyvu1o023CbzW5OL4KOVCHQPBarIJVaFoYLG8aILIx01kk7sTwsVGR0YpKS3tThVm6KFI0jp1zkeCTLBHF3FPMdWKvqyu4BQwVVpihOxDyoB8pQWWHRvogSbowzho8g7Mc0113GcSK-uM-HXMleDDmWOYkhj0fwe2iybNNtvFd5_EpQLy1EQonskxHs95LLu6XZ5MNEGsHP4S-uKXKUFJWtn5scAYdCwxHb77bifukZEVjEhfr-bs_78MnH_Png7h-wtnp6tgdou6zKsZ-hWKrsfAzrJ9OzaYbf6ezq-u9_RVnvJw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hkGilChX6WqDgQ3upFDUbO4mDVKGqsCyFRT0sEjc38QNVgmQhixA_iv_YGeeBOMANRckltg-e8Xg-z3g-gC9CZsJliFRdgdgEDV4aFKm0AY_tUDghrA7pcvLkJBmfit9n8dkC3Hd3YSitsrOJ3lCbStMZ-XcioMZHDndnVwGRRlFwtWPQaLTiyN7dImKrfxzuoXi_RtFof_prHLSkAoHmsZgHWarT3HBhwxg9a5M661I7tDzMZWR0YpKC3szhVmbyDJ0DJ13keJQWCeLOiEgi0OIvCc4zWlBydNAHLQi8EL5DTBKkuJS6IGroa5Yizgg8kwglnMSPtsE3s7xGibiGSuNpX9fveaO3sNI6q-xno12rsGDLNVietOH4d3A92jtgf_an7N-lJztilWN-c7y4Y11yATvPiRpEM02sRSWlI-0wTZwgTRYeo5NgZktT0QUZbJeXhvkqyESW3Jlm5mPr5Xn9Hk5fZL4_wGJZlfYTMDSIRYbqgxgL7U4RSiss-jNRwo1xxvABhN2cKt1WOCeijQvV12b2YlD4VSQGFQ_gW99l1pT3eK7x1iNBPfQQCRXOTwaw0UlOtaagVr3iDmC7_4trmAIzeWmrm1ohwJHoqGL_j424H0ZGxBdxIdefHXkbXo2nk2N1fHhytAGvfb6hTyzfhMX59Y39jH7TvNjy2srg70svj_8YXSjc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS91AFD6IBSkUaWsft1qdRd0IwSQzySQFKcXrrdYHLhTubprMQwqa3JorxZ_mv_OcyUNc6E5CssnMLHIec76cM-cD-CayXLgckaorEZugw5NBKTMb8MRGwglhdUiHk49P0v1z8XuaTBfgrj8LQ2WVvU_0jtrUmv6RbxMBNV5ZtO26qojT8eTH7F9ABFKUaO3ZNFoNObS3_xG9NTsHYxT1ZhxP9s5294OOYCDQPBHzIJdaFoYLGyYYZRvprJM2sjwsstjo1KQl3bnDbc0UOQYKLnOx47EsU8SgMRFGoPd_JXkSkYnJ6YD1IgIyhPUQnwQSzapPqIa-fylijsCzilDxSfJoS3wzKxqUjmtpNZ6Oe_3-N3kLy13gyn62mvYOFmz1HpaOu9T8ClxPxr_Y6d4Z-3vliY9Y7ZjfKC9vWV9owC4KognRTBODUUWlSd-ZJn6QtiKP0V9hZitT02EZHFdUhvmOyESc3Ltp5vPs1UXzAc5f5Ht_hMWqruxnYOgcyxxVCfEW-qAyzKywGNvEKTfGGcNHEPbfVOmu2zmRblyqoU-zF4PCpyIxqGQEW8OUWdvq47nB648E9TBDpNREPx3Bai851bmFRg1KPIKN4S3aMyVpisrWN41CsJNh0IrzP7XiflgZ0V_MRfbl2ZU3YAkNQx0dnByuwmtfeuhrzNdgcX59Y79iCDUv172yMvjz0tZxD73hLQk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FDG+PET+imaging+of+locally+advanced+gastric+carcinomas%3A+correlation+with+endoscopic+and+histopathological+findings&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Stahl%2C+Alexander&rft.au=Ott%2C+Katja&rft.au=Weber%2C+Wolfgang&rft.au=Becker%2C+Karen&rft.date=2003-02-01&rft.issn=1619-7070&rft.eissn=1619-7089&rft.volume=30&rft.issue=2&rft.spage=288&rft.epage=295&rft_id=info:doi/10.1007%2Fs00259-002-1029-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00259_002_1029_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon